All lobbying filings
AVENUE SOLUTIONS
AVENUE SOLUTIONS filed a Q2 report for JAZZ PHARMACEUTICALS, INC. on July 20, 2026, reporting $50,000 in lobbying income.
Lobbying for JAZZ PHARMACEUTICALS, INC. · Specialty pharmaceuticals
Filing · LD-2 quarterly report
Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
California
Lobbying activity
2
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act